CS
MACK

Candriam SCA’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Candriam SCA’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,420
Closed -$291K – 792
2017
Q3 		$291K Sell
25,420
-67,363
-73% -$708K 0.01% 699
2017
Q2 		$905K Sell
92,783
-16,396
-15% -$335K 0.02% 589
2017
Q1 		$2.65M Buy
109,179
+76,896
+238% +$1.92M 0.05% 386
2016
Q4 		$1.04M Buy
32,283
+3,813
+13% +$163K 0.02% 511
2016
Q3 		$1.42M Buy
28,470
+889
+3% +$36.9K 0.03% 428
2016
Q2 		$1.17M Hold
27,581
– – 0.03% 406
2016
Q1 		$1.81M Sell
27,581
-1,703
-6% -$88.9K 0.05% 338
2015
Q4 		$1.82M Hold
29,284
– – 0.05% 311
2015
Q3 		$1.96M Buy
29,284
+4,499
+18% +$367K 0.05% 345
2015
Q2 		$2.41M Buy
+24,785
New +$2.36M 0.05% 333

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA's MACK Position: Q4 2017 in Review

Candriam SCA sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 25,420 shares — an estimated $291K sold.

Candriam SCA first reported a position in MACK in Q2 2015 and held it in 10 quarters. The position peaked at $2.65M in Q1 2017. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

  • Candriam SCA reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Candriam SCA sold 25,420 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $291K.
  • Candriam SCA first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
  • Candriam SCA's Merrimack Pharmaceuticals, Inc. position peaked at $2.65M in Q1 2017.
  • 78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Candriam SCA's 13F filing for Q4 2017, filed 7 Feb 2018.